By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galectin Therapeutics 

7 Wells Avenue
Suite #34
Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


Company News
Galectin (GALT) Reports 2017 First Quarter Financial Results And Provides Business Update 5/15/2017 7:24:20 AM
Galectin (GALT) Launches The Liver Line, An Online Community And Publication On Liver Health And Liver Disease 5/3/2017 8:50:24 AM
Galectin (GALT) Receives Notice Of Japanese Decision To Grant A Composition Of Matter Patent For GR-MD-02 4/25/2017 8:17:33 AM
Galectin (GALT)’s GR-MD-02 Demonstrates Efficacy In Patients With Moderate To Severe Plaque Psoriasis 3/6/2017 8:40:00 AM
Galectin (GALT) Stock Craters After Phase IIa NASH Failure 9/28/2016 5:55:29 AM
Galectin Reports Second Quarter 2016 Financial Results And Provides Business Update 8/9/2016 8:39:19 AM
Peter G. Traber, M.D., CEO And CMO Of Galectin, To Speak On The Medical Applications Of Plant-Derived Complex Carbohydrates 7/13/2016 10:24:15 AM
Galectin Receives Notice Of Australian Patent To Be Granted For The Use Of GR-MD-02 In Liver, Kidney, Lung Or Heart Fibrosis 7/12/2016 10:14:04 AM
Galectin Announces Pricing Of $9.8 Million Registered Direct Offering 11/20/2015 7:59:44 AM
Research Underlying Galectin's Development Of GR-MD-02 In Cancer Presented At The Society For Immunotherapy Of Cancer Annual Meeting 11/11/2015 8:04:31 AM